Government of Canada invests $10 million in research on outpatient medications for COVID-19
When COVID-19 first emerged, the Government of Canada and the research community quickly stepped up to develop testing approaches, public health measures, and new vaccines to protect Canadians from the health challenges of the COVID-19 pandemic. The Government of Canada is also investing in safe and effective COVID-19 therapeutics, including antiviral medications. In response to the pressing need to further evaluate the clinical and cost effectiveness of these treatments in non-hospitalized patients, the Canadian Institutes of Health Research joined forces with Health Canada and the Public Health Agency of Canada.
Today, the Honourable Jean-Yves Duclos, Minister of Health, announced an investment of $10 million under this collaboration. We are excited that Simone Dahrouge, PhD and investigator at the Bruyère Research Institute, will be contributing to this pan-Canadian platform that will advance research into the effectiveness and clinical challenges of new COVID-19 treatments in community settings.
This research will evaluate whether select treatments prevent hospitalization and post COVID-19 condition (“long COVID”), offering timely evidence to clinical researchers, health system managers, and public health officials in Canada and abroad.
As a part of the evaluation, patients in the Ottawa region will have access to treatments through the Ottawa Practice Enhancement Network.
We invite you to follow along by signing up for updates: www.CanTreatCOVID.org
Read the full release here.